RE:RE:ONCY’s Phase 1b/2 mPC results compared over 2019 to 2023Pelareorep (pela) + atezolizumab (atezo) and chemotherapy in first-line (1L) advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) patients – Results from the GOBLET study
Conclusions/Results –
• The study treatment combination, pela, atezo and gemcitabine/nab-paclitaxel, resulted in tumor responses greatly surpassing historical outcomes (Von Hoff, et al., NEJM 2013) in 1L PDAC patients: 62% overall ORR, with a confirmed ORR of 54% and a DCR of 85%.
• The study yielded encouraging PFS, OS, and 12-month survival rates.
• The treatment combination was well tolerated.
• Translational results support pela’s immunologic mechanism of action:
o Study treatment resulted in the expansion of T cell clones in the blood, including both preexisting and new TIL-specific clones.
o Expansion of TIL clones appears to correlate with tumor response.
• Pela, atezo, and gemcitabine/nab-paclitaxel will be evaluated as an arm in the Ph3 Precision Promise study. In addition, the novel combination of mFOLFIRINOX + pela +/- atezo will be investigated as a new arm in the GOBLET study.
Study Authors :
Dirk Arnold 1 , Eray Goekkurt 2 , Alexander Stein 2 , Uwe M. Martens 3 , Jack Chater 4 , Guy Ungerechts 5 , Houra Loghmani 6 , Matt Coffey 6 , Richard Trauger 7 , Thomas Heineman 7
Asklepios Tumorzentrum Hamburg, AK Altona, Hamburg, Germany 1 ,
Hematology-Oncology Practice Eppendorf (HOPE),Hamburg, Germany 2 ,
SLK-Kliniken Heilbronn GmbH, Heilbronn, Germany3 ,
Klinikum Chemnitz GmbH, Germany 4 ,
Department of Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and University Hospital Heidelberg (UKHD), Germany 5 ,
Oncolytics Biotech Inc., Calgary, Canada 6 ,
Oncolytics Biotech Inc, San Diego, USA 7